Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 14/20 | 0.38 |
| ▸ | THRB | P10828 | 14/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449535 | 0.88 | THRA (0.35) | ESR1ESR2THRATHRBCYP2D6 | |
| SCHEMBL1417388 | 0.85 | AMY1A (0.45) | ESR1ESR2THRATHRBCYP1A2 | |
| SCHEMBL4455311 | 0.83 | NUDT1 (0.34) | ESR1ESR2THRATHRB | |
| SCHEMBL4451915 | 0.83 | NUDT1 (0.37) | THRATHRB | |
| SCHEMBL2201491 | 0.83 | ESR1 (0.56) | ESR1ESR2THRATHRBCYP1A2 | |
| SCHEMBL4449524 | 0.82 | ESR1 (0.41) | ESR1ESR2THRATHRBCYP1A2 | |
| SCHEMBL4456963 | 0.81 | ESR1 (0.40) | ESR1ESR2THRATHRBCYP1A2 | |
| SCHEMBL7526030 | 0.81 | ESR1 (0.59) | ESR1ESR2THRATHRBCYP1A2 | |
| SCHEMBL16664780 | 0.81 | ESR1 (0.39) | ESR1ESR2THRATHRBCYP1A2 | |
| SCHEMBL12799169 | 0.80 | ESR1 (0.53) | ESR1ESR2THRATHRBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7586009-B2 | Bis-(hydroxybenzaldehyde) compound and novel polynuclear polyphenol compound derived therefrom and method for production thereof | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090076310-A1 | NOVEL BIS-(HYDROXYBENZALDEHYDE) COMPOUND AND NOVEL POLYNUCLEAR POLYPHENOL COMPOUND DERIVED THEREFROM AND METHOD FOR PRODUCTION THEREOF | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076310-A1 | NOVEL BIS-(HYDROXYBENZALDEHYDE) COMPOUND AND NOVEL POLYNUCLEAR POLYPHENOL COMPOUND DERIVED THEREFROM AND METHOD FOR PRODUCTION THEREOF | DDT, PAH, HPD | ESR1 1880/4885ESR2 2910/4885THRA 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.